Cargando…

Impact of MET inhibition on small‐cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway

Small‐cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers, and is characterized as extremely aggressive, often displaying rapid tumor growth and multiple organ metastases. In addition, the clinical outcome of SCLC patients is poor due to early relapse and acquired resistance t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taniguchi, Hirokazu, Yamada, Tadaaki, Takeuchi, Shinji, Arai, Sachiko, Fukuda, Koji, Sakamoto, Shuichi, Kawada, Manabu, Yamaguchi, Hiroyuki, Mukae, Hiroshi, Yano, Seiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497807/ https://www.ncbi.nlm.nih.gov/pubmed/28474864 http://dx.doi.org/10.1111/cas.13268

Ejemplares similares

MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements
por: Takumi, Yohei, et al.
Publicado: (2022)

Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib‐resistance of EML4‐ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors
por: Taniguchi, Hirokazu, et al.
Publicado: (2016)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
por: Nakade, Junya, et al.
Publicado: (2014)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
por: Jardim, Denis L. Fontes, et al.
Publicado: (2014)

Molecular mechanisms controlling the phenotype and the EMT/MET dynamics of hepatocyte
por: Cicchini, Carla, et al.
Publicado: (2015)

Hepatocyte growth factor/MET in cancer progression and biomarker discovery
por: Matsumoto, Kunio, et al.
Publicado: (2017)

In vivo imaging xenograft models for the evaluation of anti‐brain tumor efficacy of targeted drugs
por: Kita, Kenji, et al.
Publicado: (2017)

MET amplification as a potential therapeutic target in gastric cancer
por: Kawakami, Hisato, et al.
Publicado: (2012)

Hepatocyte Growth Factor/c-Met Signaling Is Required for β-Cell Regeneration
por: Alvarez-Perez, Juan Carlos, et al.
Publicado: (2014)

MET Gene Copy Number Alterations and Expression of MET and Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas
por: Schmitz, Katja, et al.
Publicado: (2015)

Characterizing the roles of Met31 and Met32 in coordinating Met4-activated transcription in the absence of Met30
por: Carrillo, Emilio, et al.
Publicado: (2012)

In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET
por: Arai, Sachiko, et al.
Publicado: (2017)

PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells
por: Crosswell, Hal E, et al.
Publicado: (2009)

Met carriers of the BDNF Val66Met polymorphism show reduced Glx/NAA in the pregenual ACC in two independent cohorts
por: Martens, Louise, et al.
Publicado: (2021)

Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases
por: Whang, Young Mi, et al.
Publicado: (2019)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
por: Nanjo, Shigeki, et al.
Publicado: (2015)

Critical Role of MetR/MetB/MetC/MetX in Cysteine and Methionine Metabolism, Fungal Development, and Virulence of Alternaria alternata
por: Gai, Yunpeng, et al.
Publicado: (2021)

Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR‐mutant lung cancer
por: Fukuda, Koji, et al.
Publicado: (2020)

Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report
por: Tanimoto, Azusa, et al.
Publicado: (2018)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells
por: Tate, Amanda, et al.
Publicado: (2006)

Recent progress in the imaging of c‐Met aberrant cancers with positron emission tomography
por: Floresta, Giuseppe, et al.
Publicado: (2022)

Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros
Publicado: (1995)

The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment
por: Parikh, Rahul A, et al.
Publicado: (2014)

Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors
por: Smyth, Elizabeth C, et al.
Publicado: (2014)

Functional and therapeutic relevance of hepatocyte growth factor/c‐MET signaling in synovial sarcoma
por: Imura, Yoshinori, et al.
Publicado: (2016)

Editorial of Special Issue “New Aspects of the Hepatocyte Growth Factor/c-Met System”
por: Ricci, Giulia
Publicado: (2015)

Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment
por: Rothenberger, Natalie J., et al.
Publicado: (2017)

Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2021)

Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102
por: Buchanan, Ian M, et al.
Publicado: (2011)

Met inactivation by S-allylcysteine suppresses the migration and invasion of nasopharyngeal cancer cells induced by hepatocyte growth factor
por: Cho, Oyeon, et al.
Publicado: (2015)

A sequential EMT-MET mechanism drives the differentiation of human embryonic stem cells towards hepatocytes
por: Li, Qiuhong, et al.
Publicado: (2017)

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study
por: Shimokawa, Mototsugu, et al.
Publicado: (2020)

Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells
por: Petti, Consalvo, et al.
Publicado: (2014)

Meeting an un-MET need: Targeting MET in non-small cell lung cancer
por: Michaels, Elena, et al.
Publicado: (2022)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
por: Presutti, Dario, et al.
Publicado: (2015)

Tackling CASMI 2012: Solutions from MetFrag and MetFusion
por: Ruttkies, Christoph, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0agkkl3u1tpv7hdelr2jd90hau